Mid-manufacturing storage: Antibody stability after chromatography and precipitation based capture steps

Walpurga Krepper¹ | Daniel Burgstaller¹ | Alois Jungbauer¹,² | Peter Satzer¹

¹Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria
²Austrian Centre of Industrial Biotechnology (ACIB), Vienna, Austria

Correspondence
Alois Jungbauer, Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna (BOKU), Muthgasse 18, 1190 Vienna, Austria.
Email: alois.jungbauer@boku.ac.at

Funding information
H2020 LEIT Biotechnology, Grant/Award Number: 635557

Peer Review
The peer review history for this article is available at https://publons.com/publon/10.1002/btpr.2928.

Abstract
Antibodies of the IgG2 subclass were captured from the clarified cell culture fluid either by protein A chromatography or by polyethylene glycol precipitation. The captured intermediates were stored as neutralized eluates (protein A chromatography) or in solid form as polyethylene glycol precipitates over a period of 13 months at three temperatures, −20°C, 5°C, and room temperature to compare the capture technologies in regard of the resulting product storability. Monomer content, high molecular mass impurities product loss and changes in the composition of the charge variants were determined at six time points during the storage. At the beginning and end of the study, samples were additionally tested by differential scanning calorimetry, differential scanning fluorimetry, and circular dichroism to determine structural alterations occurring during storage. Protein A purified material was highly stable at all tested temperatures in regard of monomer content and product losses. A transient, acidic isoform was formed during the chromatography step which re-converted to the main charged variant upon storage within a matter of days. Precipitated antibodies could be stored at −20 or 5°C for 3 months without product losses but afterwards recovery yields dropped to 65%. At room temperature, the precipitated antibody was not stable and degraded within 3 months.

KEYWORDS
chromatography, immunoglobulin, precipitation, storability, storage

1 | INTRODUCTION

Stability and shelf life of formulated antibodies have been studied extensively but there is limited data available for process intermediates. Research is classically based on ideal storage conditions for final drug formulations¹⁻³ but nowadays biopharmaceutical operations are often conducted on a global scale and the materials might be shipped mid-manufacturing. In 2016, the European Medicine Agency (EMA) published a guideline on process validation for the manufacturing of biotechnology-derived products⁴ where they recommend to evaluate the impact of hold steps, mid-manufacturing storage, and transportation on process intermediates. To determine the influence of unexpected process interruptions on the intermediate, they suggest to perform studies under worst-case and non-standard conditions. Furthermore, intermediate characterization is crucial for process development, design of hold steps, and development of in-process control methods. Therefore, protein alterations and stability at all stages during processing are important.

Stability studies are time and cost consuming, since the samples must be stored under the respective temperature and conditions for the projected time period to get good quality data. Accelerated shelf-life studies have been suggested in which the sample is stored at higher temperature and then possible storage time at lower temperature is extrapolated using the Arrhenius equation.⁵ For elaboration of
shelf-life some quality parameters reflecting the degradation of the protein must be determined.

All proteins, including recombinant antibodies, are susceptible to alterations during production, processing, and storage. Common modifications of antibodies are sialylation, glycosylation, deamidation, oxidation, N-terminal pyroglutamine cyclization, C-terminal lysine cleavage, aspartate isomerization, and disulfide bond shuffling. These modifications give rise to a high degree of microheterogeneity and can affect antibody functionality and stability. It is not possible to capture all these variants therefore surrogate parameters are used during product and process development. Importance has however to be put on the identification of critical protein modifications in order to limit degradation pathways and define optimum storage conditions in regard of temperature, humidity, and light irradiation.

Rapid methods to investigate antibody destruction during storage are usually HPLC based with the most widely used techniques being size exclusion chromatography, cation-exchange chromatography or content analysis by affinity chromatography. Such methods capture the aggregate formation, degradation/clipping of the antibody to a smaller molecular variant and formation of charge variants.

Nowadays, the majority of antibody products are produced in mammalian host cell lines and after primary recovery, the purification is based on protein A chromatography which typically results in yields around 95% and purities >98%. Due to the high affinity of protein A towards antibodies and the high capacities achieved by modern protein A materials, the protein solution is rather concentrated and pure at this stage. The high antibody concentration in combination with the harsh, acidic elution conditions can promote the formation of aggregates and therefore potentially to a loss in product. Also, protein A chromatography material is rather expensive, adding significantly to the overall process costs, especially in early development phases when the material is not utilized to its maximum lifetime. Therefore, several groups – including our own – have presented alternative approaches for antibody capture steps in recent years, for example, by mixed-mode chromatography, aqueous two-phase extraction or precipitation.

Precipitation offers a viable, non-chromatographic alternative which can be easily customized for continuous manufacturing. It scales only with volume and is able to deal with varying titters in the upstream feed. Burgstaller et al. recently demonstrated that polyethylene glycol (PEG) precipitation in combination with tangential microfiltration results in similar purity and process yields as protein A chromatography. In a PEG precipitation capture step, the solubility of the antibody in the clarified culture supernatant is lowered by addition of PEG leading to precipitation of the product. The solid precipitate is harvested by microfiltration and resolubilized in a dissolution buffer. The antibody is thereby concentrated and host cell proteins (HCPs) are largely depleted. To meet the requirements in regard of purity for drug products, the protein has to be further processed by at least one more polishing step before it will be transferred into a formulation buffer by an ultra-/diafiltration step.

In this work, we compared two antibody capture technologies in regard of effects on the intermediate storability. Antibodies were captured either by protein A chromatography or by precipitation from the clarified cell culture fluid. The protein A eluate was neutralized and stored in liquid phase. The precipitated material was stored in its solid form after decantation of the supernatant. Samples were then stored under identical conditions at three temperatures (−20°C, 5°C, and room temperature) for 13 months. Storage at −20°C and 5°C are typical storage conditions for biopharmaceutical intermediates awaiting further processing. Storage at room temperature (ambient, non-monitored) was included as a worst-case scenario. The EMA guideline for process validation recommends tests at higher temperatures and for elongated times to substantiate the recommendations for ideal intermediate handling during manufacturing. In both cases, the material was stored mid-manufacturing without performing any additional processing steps before storage. It should be noted that this results in different high molecular weight impurities (HMWI) and low molecular weight impurities (LMWI) concentrations for the two pools since protein A chromatography is more efficient in HCP clearance. The precipitated material is stored under precipitation conditions, that is, 13.2% (w/w) of polyethylene glycol are present. Storage of the material in its precipitated form poses the advantages that less volume is being stored which leads to a decrease in storage costs.

The reconstituted material was tested by HPLC based methods (size exclusion and cation exchange pH gradient) at six time points during storage (starting material and after 1, 3, 6, 10, and 13 months at the respective temperature). Starting and end material were additionally probed by differential scanning calorimetry (DSC), differential scanning fluorimetry (DSF), and circular dichroism (CD) to identify structural changes during storage.

## 2 | MATERIAL AND METHODS

All chemicals were of analytical grade and purchased from Sigma-Aldrich (St. Louis, MO), unless stated otherwise.

### 2.1 | Antibodies

Experiments were carried out with recombinant, human antibodies of the subclass IgG2. We used clarified cell culture fluid (CCCF) of a CHO run with an antibody monomer concentration of 3.3 g/L. The antibodies were then either captured by protein A chromatography (chapter 2.1.1) or precipitation (chapter 2.1.2) using CCCF from the same CHO run.

#### 2.1.1 | Protein A chromatography

Protein A chromatography was carried out on Mab Select SuRe resin (GE Healthcare, Sweden). Column was equilibrated with 50 mM Na-phosphate at pH 7.0 and washing was performed with 100 mM Na-citrate at pH 5.5. Antibodies were eluted by a single step gradient using 100 mM Na-acetate at pH 3.6. They were then incubated at pH 3.6 for 1 hr before the pH was readjusted to 6.0.
2.1.2 | Precipitation

Polyethylene glycol with an average molecular weight of 6,000 Da was used for antibody precipitation as described in previous publications. In short, a stock solution of 40% PEG6000 (w/w) was prepared in a 100 mM Tris buffer (pH 7.5). The CCCF was mixed in a polypropylene tube with the stock solution to a final PEG concentration of 13.2% (w/w). Then, the solution was mixed on a mechanical end-over-end shaker (Cole-Parmer, IL) for 10 min. The precipitate was centrifuged for 5 min at 2,000 rcf and the liquid phase decanted. The precipitate was washed with a solution of 13.2% PEG in 100 mM Tris buffer (pH 7.5) (gravimetrically determined to be the same amount as previously removed) and again incubated on the shaker for 10 min. After another centrifugation (5 min at 2,000 rcf), the CCCF was decanted and the precipitate was put into storage. Before analysis, the precipitated antibody was reconstituted in the same volume previously and the precipitate was put into storage. Before analysis, the precipitated material was stored in the precipitated form after neutralization. Protein A purified material was stored in liquid form after neutralization. In both cases, protein A purification and precipitation, the material was stored without performing any additional process steps. The protein A purified material was stored in liquid form after neutralization. The precipitated material was stored in the precipitated form after removal of the supernatant. Conical, lightproof polypropylene tubes were used for storage. Storage at –20°C was done in a standard lab freezer from Electrolux (Stockholm, Sweden) and storage at 5 ± 3°C was done in a refrigerator by KBS Kältetechnik (Wiesbaden, Germany). Room temperature storage was performed in one of our labs with room temperature ranging from 20.0 to 25.0°C. This scenario was included to mimic worst-case conditions like an unexpected process interruption where fast degradation kinetics can be expected.

2.2 | Storage conditions

In both cases, protein A purification and precipitation, the material was stored without performing any additional process steps. The protein A purified material was stored in liquid form after neutralization. The precipitated material was stored in the precipitated form after removal of the supernatant. Conical, lightproof polypropylene tubes were used for storage. Storage at –20°C was done in a standard lab freezer from Electrolux (Stockholm, Sweden) and storage at 5 ± 3°C was done in a refrigerator by KBS Kältetechnik (Wiesbaden, Germany). Room temperature storage was performed in one of our labs with room temperature ranging from 20.0 to 25.0°C. This scenario was included to mimic worst-case conditions like an unexpected process interruption where fast degradation kinetics can be expected.

2.3 | Nano differential scanning calorimetry (nanoDSC)

Samples were dialyzed in Slide-A-Lyzer cassettes (Thermo Fisher Scientific, Waltham, USA) with a molecular weight cut-off (MWCO) of 10,000 Da to a 20 mM sodium phosphate buffer, pH 6.9 and then diluted to a concentration of 3 mg/mL. The solution was loaded into the sample cell of a TA-Instruments Nano DSC instrument (model: 602000). The reference cell was filled with a solution containing 0.5 M NaCl, 0.1 M acetic acid, and 1 mg/mL pepsin which was incubated for 3 hr at 37°C and then flushed with 2 L of water. The obtained thermogram data were analyzed using the TA Instruments NanoAnalyse software. Buffer blanks were subtracted from all samples.

2.4 | Circular dichroism (CD)

Circular dichroism spectra were obtained on a Chirascan CD Spectrometer from Applied Photophysics (Surrey, UK). The samples were diluted to concentrations of 0.3 g/l and measured in cells with a path length of 0.1 cm. Spectra were obtained in the range of 180 to 260 nm. The bandwidth was set to 1 nm and the signal was averaged over 10 s. The detector reached saturation at 195 nm, therefore, data in the range from 195 to 260 nm is shown.

2.5 | Size exclusion chromatography (SEC)

SEC was used to assess the monomer and HMWI content and product losses. Experiments were carried out on a Dionex UltiMate 3000 HPLC system (Thermo Fisher Scientific, Waltham). Isocratic elution was carried out with a 50 mM sodium phosphate buffer with 150 mM NaCl at pH 7.0. 10 μL of 0.22 μm filtered sample were applied to a TSKgel® G3000SWXL HPLC column (5 μm; 7.8 mm × 300 mm) with a TSKgel® SWXL guard column (7 μm; 6.0 × 40 mm) (both Tosoh, Japan). Chromeleon™ 7 software (Thermo Scientific) was used to monitor the signals at 215 nm (for HMWII) and 280 nm (for monomer content and product loss). The starting material is referred to as T0 material. Monomer content is based on the ratio of product peak area (monomer, detected at 280 nm) to the sum of all peak areas. HMWI are calculated by taking the sum of all peaks eluting before the main antibody peak (at 215 nm) and dividing it by the sum of main peak and earlier eluting species. Concentration in relation to T0 is the ratio between the monomer peak at 280 nm of the respective sample with the T0 sample of the respective capture method (protein A or precipitation). Average values and standard deviations are based on triplicate measurements. Injection volume and dilutions were kept constant for all samples.

2.6 | Isoform characterization by pH gradient chromatography

Antibody isoforms were monitored by a cation exchange (CIEX) HPLC method based on a pH gradient method developed by Lingg et al. In short, measurements were performed on a Dionex UltiMate 3000 HPLC system (Thermo Scientific). A ProPac™ WCX-10G Guard Column (10 μm, 4 × 50 mm) and a ProPac™ WCX-10 column (10 μm, 4 × 250 mm) (both Thermo Scientific) were used as stationary phase. Samples were diluted to 1 g/L and the injection volume was 100 μL. The flow rate of the method was set to 1 ml/min. The column was equilibrated for 1 CV at 100% A, before a 12 CV gradient from 0 to 100% B was performed. The method ended with a 1 CV wash step at 100% B. Mobile phase A was 5.5 mM HEPES, 4.2 mM Bicine, 9.5 mM CAPSO, 0.8 mM CAPS and 6.3 mM NaCl (pH 8.0). Mobile phase B was 10.5 mM Bicine, 2.5 mM CAPSO, 7.0 mM CAPS (pH 10.5). The outlet was monitored at 280 nm. The most abundant isomer is defined as main charge variant (MCV). Isoforms eluting earlier than the MCV are called acidic variants, later eluting ones are called basic variants. Accuracy, precision and the lower limit of quantification of
the method can be found at Lingg et al. \textsuperscript{19} Injection volume and dilutions were kept constant for all samples.

2.7 | Nano differential scanning fluorimetry (nanoDSF)

Nano differential scanning fluorimetry measurements were performed on a Tycho NT.6 (Nanotemper, Germany). Samples were diluted with 25 mM Tris (pH 7.5) to a concentration of 1 g/L and taken up in glass capillaries which were placed in the nano differential scanning fluorimeter. Initial temperature was set to 35°C and the ramp-up rate was set to 30°C/min. Spectra were taken between 35 and 95°C.

3 | RESULTS

3.1 | Monomer content, HMWI, and product loss

To determine the stability of the antibody intermediate, we used clarified cell culture supernatant and purified it either by a conventional protein A chromatography step or by precipitation of the antibody with PEG at a concentration of 13.2% (w/w). The protein A eluate was kept at the elution pH of 3.6 for 1 hr and then readjusted to the storage pH of 6.0. The PEG precipitated sample was stored in its solid form and in the presence of 13.2% polyethylene glycol. To simulate different intermediate storage conditions, samples were stored at three different temperatures. Storage at −20 and 5°C corresponds to typical storage conditions mid-manufacturing while storage at room temperature was included as a worst-case condition where rapid degradation kinetics are expected. The material was stored for a total of 13 months. Multiple aliquots for both protein A purified and precipitated material were stored at these temperatures and for each analysis an independent aliquot was used and discarded after analysis to avoid repeated freeze–thaw cycles of samples. Samples were tested at the start and after 1, 3, 6, 10, and 13 months in storage with different methods for monomer content, aggregates and product losses. Changes in protein structure were determined by CD, DSC, and DSF. Figure 1 shows the composition of the samples before and after capture step. HMWI as well as LMWI present in the CCCF are more efficiently removed by protein A chromatography than by precipitation. For further information regarding the efficiency of precipitation methods in comparison to affinity chromatography, see Sommer et al. \textsuperscript{14,20} and Hammerschmidt et al. \textsuperscript{15}

Figure 2 gives the monomer content for both purification techniques at the three tested temperatures. Over the testing period of 13 months, the monomer content of the protein A purified samples decreases approximately 2% from 99.8% at \( T_0 \) to −98% at all tested temperatures. This decrease is mirrored by a rise in HMWI (Figure 3).

For the precipitated antibody, the monomer content (purity) stays constant at −20°C, decreases slightly at 5°C and strongly when stored at room temperature. For the material stored at 5°C, the monomer loss is counteracted by an increase in HMWI. The monomer content of the precipitated material decreases at a constant rate over the observation period. However, HMWI stay constant for the first 6 months in storage and start rising only afterwards. Therefore, the monomer loss of the first 6 months has to be the result of degradation processes leading to the formation of LMWI. Generally, the HMWI content in the precipitated samples is around 5% at the start of the storage, while it is less than 1% for the protein A purified samples.

We do not observe any product losses for the protein A purified materials at any temperature (Figure 4). For the precipitated material,
the picture looks quite different. The product loss of the material stored at \(-20\) and \(5^\circ\)C is less than 10% if reconstituted within 1 month but if the precipitate is stored longer than that, the losses increase to 30 to 35%. To keep recovery yields high, it is therefore necessary to reconstitute the precipitated material within the first month of storage.

For the precipitated material stored at room temperature, we observe a small product loss during the first 3 months of storage, afterwards the SEC HPLC data indicate no product losses resulting in resolubilization yields above 100% [sic] after 13 months. While the overall yield is stable at 100%, the product is unstable at room temperature. We assume degradation into product related impurities (degradation products) as the yield is stable, but the monomer content of the sample drops down to 60% during storage at room temperature. Due to the results regarding monomer content (Figure 2), HMWI (Figure 3), and charged variants (Figure 5), we assume that the antibody is degraded after 13 months of room temperature storage and that the degraded antibody has a higher UV absorbance than the native form explaining a yield above 100%. Since obtaining product losses less than 0% is virtually impossible, we assume that tryptophan residues which are buried in the hydrophobic core of the native protein are becoming exposed to the hydrophilic solvent due to the loss of conformation and therefore increase the UV signal. The data shown in Figures 2 and 3 is presented in tabular form in as well (Table S1).

### 3.2 Acidic variants formed during protein a chromatography

#### 3.2.1 Variant alterations during storage

Isoform composition of the stored material was determined at six time points during storage of 13 months for the materials stored at \(-20\)°C, 5°C, and room temperature to catch any changes in the isoform composition indicating possible degradation of the antibody during storage. The \(T_0\) sample of the protein A purified material was additionally tested for isoform pattern changes in the first 120 hr of storage at temperatures 5°C, room temperature, and 40°C since we detected an acidic variant in the starting material that vanished in storage within the first month. We hypothesized that the formation of the acidic variant could be a result of the low pH hold step after protein A elution, therefore we prepared a sample of precipitated material resolubilized and stored for 1 hr at low pH to capture any changes in isoform composition which are not due to the protein A purification itself, but due to the following low pH viral inactivation. Figure 6 shows a pH gradient HPLC chromatogram of the antibody before capture of clarified cell culture fluid (CCCF), the samples of the protein A purified material and the precipitated material after low pH incubation before storage.

Protein A chromatography leads to the formation of a new isoform in the sample which is more acidic than the one present in the CCCF while precipitation or viral inactivation at low pH does not result in formation of any new variants. In this chapter, we will however focus on the alterations during long-term storage while the formation of the acidic variant during protein A chromatography is dealt with in more detail in chapter 3.2.2. Figure 7a shows the protein A purified material during long term storage at \(-20\)°C. As we can see, the acidic variant is converted into the MCV within the first month of
storage. Afterwards, the isoform pattern is stable again. The precipitated antibody stored at −20°C depicts a stable isoform pattern over the monitoring period (Figure 7b).

At 5°C (Figure 8), we observe the same trend as at −20°C, the acidic variant in the protein A purified sample turns into the MCV while the precipitated antibody shows a stable isoform pattern over the whole time. For the protein A purified material stored at room temperature, we see the same course that was already described for the storage at −20 and 5°C (Figure 5a), meaning a generation of an additional isoform during protein A chromatography that is not visible anymore after 1 month in storage. After the initial conversion of the acidic isoform to the main charge variant, the pattern stays stable.

For the precipitated material stored at room temperature, the isoform pattern is only stable for 1 month (Figure 5b). After storage of 3 months, we see the appearance of new, acidic isoform and after 6 months, the sample seems to be completely degenerated with new acidic and basic variants present.

3.2.2 | Formation of acidic isoform during protein A chromatography

In recent years, multiple groups, including our own, have observed conformational plasticity of antibodies during protein A chromatography.21-23 In this work we could again observe the formation of a
transient antibody isoform. We incubated the T₀ material after protein A chromatography at three different temperatures (5°C, 20°C, and 40°C) for a total of 120 hr and tested the charged variant composition at T₀, 24, 48, and 120 hr. We were able to show that re-conversion of the acidic isoform to the MCV is temperature dependent. Figure 9a–c shows chromatograms of the pH gradient HPLC of the T₀ material after protein A purification.

When incubated at 5°C or room temperature, the acidic isoform remains visible for the first 48 hr. Between 48 and 120 hr, it is almost entirely converted to the MCV and just a small shoulder remains visible. Since the yields are stable (see chapter 3.1), we know that the acidic isoforms reforms into the MCV and is not just degraded. At an incubation temperature of 40°C, the acidic isoform is almost entirely gone after 48 hr and not detectable anymore after 120 hr showing that the kinetics are temperature dependent.

To see whether the formation of the acidic isoform results from the low pH that the antibodies are exposed to during elution in protein A chromatography or the subsequent incubation at low pH for viral inactivation. Therefore, we incubated the precipitated antibody after resolubilization in pH 3.6 for 1 hr and performed pH gradient analysis again. As seen in Figure 6, the low pH incubation does not lead to change in isoform pattern, meaning that the structure change seen for protein A purified samples is due to the chromatography itself and not the shift to low pH.

3.3 | Structural alterations during long-term storage

In addition to monomer content, product loss, HMWI, and isoform composition, we wanted to check for possible changes in the structure of the stored antibodies. For this we used DSC, DSF as well as CD. In DSC, unfolding of antibodies follows a biphasic transition where the unfolding of the Fab and CH2 domain occur approximately at the same temperature and overlap in the thermogram. The CH3 domain endures higher temperatures and unfolds a bit later. On average, the main unfolding event (Fab and CH2) of the protein A purified material lies at 73.7°C while the precipitated material unfolds at 73.3°C (Figure 10a, Table S2).

This indicates that the precipitated material is slightly less stable than the protein A purified one. At higher temperatures, we observe slight differences in the unfolding of the CH3 domains of the antibodies. We noticed that the presence of residual polyethylene glycol influences the DSC signal strongly but this was taken into account by respective blank subtractions. Also the co-presence of different host cell proteins could impact the thermal stability of the samples. In the
FIGURE 9  [a–c] Isoform pattern of protein A purified material stored at 5°C, room temperature and 40°C for 120 hr compared to CCCF. Incubation of the protein A purified material with the acidic isoform shows temperature dependent reconversion of the acidic isoform the MCV within a matter of days. CCCF, clarified cell culture fluid

FIGURE 10  (a) Differential scanning calorimetry and (b) differential scanning fluorimetry spectra for protein A purified and precipitated material at start and end points of storage. Both techniques, DSC and DSF, indicate a slight decrease in stability of the precipitated material
differential scanning fluorimetry the inflection temperature of the protein A purified samples is on average at 79.8°C and is therefore about 1°C higher than the one of the precipitated antibodies which is at 78.7°C (Figure 10b, Table S2). Due to the fast heat ramping in the DSF (30°C/min), the unfolding of the antibodies occurs in a single transition rather than a biphasic one as is usually observed in DSC experiments. In both cases (DSC and DSF), the protein A purified sample shows a slightly higher unfolding temperature than the precipitated material. This can be either due to impurities in the precipitation step later in the downstream process. The protein A purified material can therefore be stored at −20°C, 5°C, and even room temperature with similar stability.

Precipitated material can be stored at −20 and 5°C but product losses have to be expected if the material is stored for more than 1 month. To obtain yields >90%, it is necessary to reconstitute the antibody within the first month of storage, making precipitate storage an option for intermediate storage before the next process step, but not feasible for long term storage. For the protein A purified material stored at −20°C, 5°C, and room temperature as well as the precipitated material stored at −20 and 5°C, the product losses are counteracted by increases in HMWI. For the precipitated material stored at room temperature, the HMWI start rising only after 6 months but product losses are observed gradually during the whole storage period. Therefore, the initial product losses have to be a result of degradation processes which lead to the formation of LMWI. The decrease in resolubilization yields observed for the precipitated material stored at −20 and 5°C could be due to the formation of compact precipitates which are harder to solubilize. Performing a buffer resolubilization screening for the precipitates stored for longer periods (>3 months) could improve resolubilization yields. After this initial drop, the resolubilization yields remain stable for the residual storage period. Storage at room temperature is not recommended at all as it leads to formation of new isoforms and degradation starts visibly after 1 month.

4 | DISCUSSION

In our study we compared protein A purified antibody to precipitated antibody in terms of intermediate stability at different temperatures. For the protein A purified material, the storage temperature had no significant impact on monomer content, HMWI or product loss compared to the starting material. HMWI increased only by 2% during the 13 month storage period which could be easily removed in a polishing step later in the downstream process. The protein A purified material can therefore be stored at −20°C, 5°C, and even room temperature with similar stability.

We performed a series of experiments to rule out the possibility that the degradation was only visible in isoform analysis while the CD signal as it was observed for the precipitated material. Neither did the spiking of the protein A purified material with PEG concentration between 0.5 to 5%. The resulting data is presented in Figure S1.

Figure 11. Circular dichroism spectra for protein A purified and precipitated material at start and end points of storage. Deconvolution of the spectra shows that a higher amount of random coil is present.
downstream. Thereby it becomes possible to see if the alterations detected after the capture step have an impact on the final drug product. Due to our analysis, we recommend a broad pallet of analytical tools to track product variations and product alterations. While one method, for instance size exclusion, could lead to the assumption of a stable protein, another method, for instance CD, could show significant changes in the structure of the product. We at least recommend three complementary methods, while one tracks product degradations in size (SEC), one tracks product alterations in structure (CD) and one tracks product alterations in charge (ion exchange). In our case, following the product through the complete process was not possible since the process was not yet fully developed when we evaluated the stability of the capture intermediates. For production, the product alterations have to be tracked through the complete process chain.

Changes in the charged isoform pattern were detected by HPLC-CIEX with a pH gradient. We observed the formation of an acidic variant during protein A chromatography that slowly converts back into the main charged variant in the first days of storage. The kinetics of these conversions depend on the storage temperature, with a faster conversion for higher temperatures where for storage at 5°C the conversion takes a week, while at elevated temperatures of 40°C it takes only 48 hr. We were also able to show that the formation of this acidic isoform is connected to the chromatography itself. Incubation of the precipitated material at a pH of 3.6 for 1 hr does not lead to a change in the isoform pattern and a formation of this isoform due to the low pH at elution can therefore be ruled out. This confirms the findings of our previous work where it was shown that the conformational changes occur while the antibodies are adsorbed to the material. Several protein modifications are known to shift the isoelectric point of a protein to the acidic side, most commonly deamidation reactions but also C-terminal lysine cleavages, sialylation, and oxidation/reduction, but none of them are known to be completely reversible in the timeframes observed in our experiments. Others have shown that protein A chromatography can lead to significant structural changes in the antibody resulting in reduced hydrodynamic radii. Such structural changes could be the cause of the phenomenon we see in our experiments, but we observed no change of hydrodynamic radius of the antibody in our samples (data not shown).

In summary, the antibodies had better storage abilities when they were captured by protein A chromatography than by precipitation. The protein A purified material was found to be well storable at all tested temperatures. With the analytics used in this study we could not detect any structural changes within the protein A purified samples over time. Monomer content and product loss were constant over a period of 13 months. The precipitated antibodies stored at room temperature started to degrade after 3 months resulting in an increase of LMWI impurities first which are later followed by the formation of HMWI too. The reduced storability of the precipitated proteins could be due to the higher presence of HCP in the precipitated samples which could include proteases leading to degradation of the product. Especially at room temperature, the precipitated material is prone to aggregate formation as well. At −20 and 5°C, the precipitated material can be stored without any product losses but reconstitution yields suffer if the material is stored for more than 1 month. The working window is however large enough to ship the material to a different production site and conduct experiments on the material mid-manufacturing or continue processing.

ACKNOWLEDGMENTS

This work was supported by the European Union’s Horizon 2020 research and innovation program under grant agreement no. 635557.

ORCID

Alois Jungbauer https://orcid.org/0000-0001-8182-7728

REFERENCES

1. Wang W. Advanced protein formulations. Protein Sci. 2015;24(7):1031-1039.
2. Carpenter JF, Prestrelski SJ, Dong A. Application of infrared spectroscopy to development of stable lyophilized protein formulations. Eur J Pharm Biopharm. 1998;45(3):231-238.
3. Chang BS, Fischer NL. Development of an efficient single-step freeze-drying cycle for protein formulations. Pharm Res. 1995;12(6):831-837.
4. European Medicines Agency. Guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission; UK: EMA; 2016. Accessed May 27, 2019.
5. Stamper GF, Lambert WJ. Accelerated stability testing of proteins and peptides: pH-stability profile of insulinotropin using traditional Arrhenius and non-linear fitting analysis. Drug Dev Ind Pharm. 1995;21(13):1503-1511.
6. Khawli LA, Goswami S, Hutchinson R, et al. Charge variants in IgG1: isolation, characterization, in vitro binding properties and pharmacokinetics in rats. MAbs. 2010;2(6):613-624.
7. Beyer B, Schuster M, Jungbauer A, Lingg N. Microheterogeneity of recombinant antibodies: analytics and functional impact. Biotechnol J. 2018;13(1):25.
8. Fahrner RL, Knudsen HL, Basey CD, et al. Industrial purification of pharmaceutical antibodies: development, operation, and validation of chromatography processes. Biotechnol Genet Eng Rev. 2001;18(1):301-327.
9. Shukla AA, Thommes J. Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol. 2010;28(5):253-261.
10. Mazzer AR, Perraud X, Halley J, O’Hara J, Bracewell DG. Protein A chromatography increases monoclonal antibody aggregation rate during subsequent low pH virus inactivation hold. J Chromatogr A. 2015;148:983-989.
11. Pollock J, Bolton G, Coffman J, Ho SV, Bracewell DG, Farid SS. Optimising the design and operation of semi-continuous affinity chromatography for clinical and commercial manufacture. J Chromatogr A. 2013;135:17-27.
12. Pezzini J, Jocsa G, Gantier R, et al. Antibody capture by mixed-mode chromatography: a comprehensive study from determination of optimal purification conditions to identification of contaminating host cell proteins. J Chromatogr A. 2011;12(45):8197-8208.
13. Schmidt A, Richter M, Rudolph F, Strube J. Integration of aqueous two-phase extraction as cell harvest and capture operation in the manufacturing process of monoclonal antibodies. Antibodies. 2017;6(4):21.
14. Sommer R, Tscheliessnig A, Satzer P, Schulz H, Helk B, Jungbauer A. Capture and intermediate purification of recombinant antibodies with combined precipitation methods. Biochem Eng J. 2015;93:200-211.

15. Hammerschmidt N, Hobiger S, Jungbauer A. Continuous polyethylene glycol precipitation of recombinant antibodies: sequential precipitation and resolubilization. Process Biochem. 2016;51(2):325-332.

16. Grosshans S, Wang G, Fischer C, Hubbuch J. An integrated precipitation and ion-exchange chromatography process for antibody manufacturing: process development strategy and continuous chromatography exploration. J Chromatogr A. 2018;19:66-76.

17. Burgstaller D, Jungbauer A, Satzer P. Continuous integrated antibody precipitation with two-stage tangential flow microfiltration enables constant mass flow. Biotechnol Bioeng. 2019;13(10):26922.

18. Lingg N, Tan E, Hintersteiner B, Bardor M, Jungbauer A. Highly linear pH gradients for analyzing monoclonal antibody charge heterogeneity in the alkaline range. J Chromatogr A. 2013;1319:65-71.

19. Lingg N, Berndtsson M, Hintersteiner B, Schuster M, Bardor M, Jungbauer A. Highly linear pH gradients for analyzing monoclonal antibody charge heterogeneity in the alkaline range: validation of the method parameters. J Chromatogr A. 2014;1373:124-130.

20. Sommer R, Satzer P, Tscheliessnig A, Schulz H, Helk B, Jungbauer A. Combined polyethylene glycol and CaCl2 precipitation for the capture and purification of recombinant antibodies. Process Biochem. 2014;49(11):2001-2009.

21. Krepper W, Satzer P, Beyer BM, Jungbauer A. Temperature dependence of antibody adsorption in protein A affinity chromatography. J Chromatogr A. 2018;1551:59-68.

22. Gagnon P, Nian R, Leong D, Hoi A. Transient conformational modification of immunoglobulin G during purification by protein A affinity chromatography. J Chromatogr A. 2015;1395:136-142.

23. Gagnon P, Nian R. Conformational plasticity of IgG during protein A affinity chromatography. J Chromatogr A. 2016;1433:98-105.

24. Liu H, Bulscco GG, Sun J. Effect of posttranslational modifications on the thermal stability of a recombinant monoclonal antibody. Immunol Lett. 2006;106(2):144-153.

25. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520-520.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Krepper W, Burgstaller D, Jungbauer A, Satzer P. Mid-manufacturing storage: Antibody stability after chromatography and precipitation based capture steps. Biotechnol Progress. 2020;36:e2928. [https://doi.org/10.1002/btpr.2928](https://doi.org/10.1002/btpr.2928)